Results 101 to 110 of about 13,423 (179)

Erosive Potential of Commercially Available Cannabis Beverages

open access: yesClinical and Experimental Dental Research, Volume 12, Issue 3, June 2026.
ABSTRACT Objective To evaluate the erosive potential of commercially available cannabis beverages by assessing fluoride content and pH, as well as changes in microhardness and surface roughness. Materials and Methods Sixteen cannabis‐infused beverages were analyzed, with distilled water used as the control.
Budsaraporn Boonsuth   +11 more
wiley   +1 more source

Bibliometric Analysis of Cubebenes and Related Sesquiterpenes: Natural Occurrence, Biosynthesis, Pharmacological Activities, and In‐Silico‐Based Future Therapeutic Potential

open access: yeseFood, Volume 7, Issue 3, June 2026.
Cubebene‐related sesquiterpenes, found across diverse biological sources, exhibit promising pharmacological activities, including anti‐inflammatory, neuroprotective, and anticancer effects. This review highlights their molecular diversity, ADME profiles, and predicted multitarget interactions, underscoring their therapeutic relevance and potential in ...
Khadija Boualam   +4 more
wiley   +1 more source

Nutritional Composition, Therapeutic Benefits, and Functional Food Potential of Coleus amboinicus: A Comprehensive Review

open access: yesFood Science &Nutrition, Volume 14, Issue 6, June 2026.
Coleus amboinicus is a nutrient‐rich herb containing vitamins (A‐, C‐, B‐complex), minerals (Ca, Mg, Fe, K), dietary fiber, and potent bioactives such as rosmarinic acid, quercetin, thymol, and carvacrol. These compounds contribute to antioxidant, anti‐inflammatory, antimicrobial, prebiotic, and cardioprotective benefits.
Shani Upadhyay   +2 more
wiley   +1 more source

Cannabidiol Protects Against 1‐Methyl‐4‐Phenylpyridinium and Manganese‐Induced Neurotoxicity via Nod‐Like Receptor Protein 3 Inflammasome Suppression

open access: yesJournal of Biochemical and Molecular Toxicology, Volume 40, Issue 6, June 2026.
CBD oil exhibits neuroprotective effects in Parkinson's disease models by inhibiting NLRP3 inflammasome activation. It preserves dopamine levels and reduces α‐synuclein accumulation, suggesting its potential as a therapeutic strategy against neuroinflammation and neurodegeneration.
Göksun Demirel   +7 more
wiley   +1 more source

Advancing Canning Quality in Common Beans: An Integrated Farm‐to‐Can Framework Combining Breeding, Processing, and Artificial Intelligence

open access: yesLegume Science, Volume 8, Issue 2, June 2026.
ABSTRACT Common beans (Phaseolus vulgaris L.) are essential raw material for the canning industry. This article reviews recent advances in assessing canning quality and the integration of artificial intelligence (AI) into breeding methodologies aimed at developing genotypes with superior yield and canning‐quality traits.
Arash Ghaitaranpour   +2 more
wiley   +1 more source

Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends

open access: yesMed Research, Volume 2, Issue 2, Page 309-342, June 2026.
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley   +1 more source

The Synthetic Cannabinoid AKB-48 Induces Cell Death in Murine Cerebellum Through Different Signaling Pathways. [PDF]

open access: yesInt J Mol Sci
De Luca F   +11 more
europepmc   +1 more source

A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis‐Related Safety Signals

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background The applicability of spontaneous reporting systems such as the US Food and Drug Administration Adverse Event Reporting System (FAERS) to detect cannabis‐related safety signals remains unclear due to the potential for discrepant reporting patterns between pharmaceutical and non‐pharmaceutical cannabis‐derived products (CDPs ...
Priscilla O. M. V. Lopes   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy